Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00090012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2004
Completion date
March 31, 2006
Enrollment
340
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia